Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2016, XLI/242: 097-100 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2016, XLI/242: 097-100

Title: Treatment standards of the oral anticoagulant in patients with idiopathic pulmonary embolism 

Authors: Kowalski Z, Kowalski P, Grzegorek D. 

More details

08/242

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Treatment standards of the oral anticoagulant in patients with idiopathic pulmonary embolism


Kowalski Z, Kowalski P, Grzegorek D.

I Department of Internal Diseases, Voyevodish Hospital of John Paul II in Bełchatów, Poland

The optimal and the most effective treatment of pulmonary embolism is still a matter of concern and each day sees a new set of challenges for the world of medicine. The progress, has been made in recent years, improved quality of life and caused much better treatment results. This is difficult issue in patients, receiving anticoagulant therapy, because they require an individual approach and adjustability to the therapeutic possibilities. The benefits of long-term anticoagulant therapy, which decreases relapses of idiopathic venous thromboembolism and diminishes risk of thromboembolic complications, should be taking under consideration. It is still a matter of dispute the time of carrying out of treatment, especially after the first life idiopathic episode of pulmonary embolism. The purpose of this paper is an overview and a summary of the foregoing achievements concerned the standards of idiopathic pulmonary embolism treatment, expecting benefits flowing with using new oral anticoagulants, as an alternative to known for decades Vitamin K antagonist drugs. A lot of information about new oral anticoagulants speaks in favor of their use, but unknown safety of the drugs caused searching the best strategy of pulmonary embolism treatment all the time.

Key words: pulmonary embolism, vitamin K antagonist, new oral anticoagulants

Pol Med J, 2016; XLI (242); 97–100